Lindbrook Capital, LLC Myovant Sciences Ltd. Transaction History

Lindbrook Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$7.78 - $14.69 $389 - $734	-50 Reduced 35.71%	90 $1,000
Q1 2022 Apr 21, 2022	BUY	$11.38 - $16.4 $569 - $819	50 Added 55.56%	140 $2,000
Q4 2021 Jan 18, 2022	BUY	$14.31 - $23.87 $1,287 - $2,148	90 New	90 $1,000
Q3 2021 Nov 05, 2021	SELL	$18.94 - $26.99 $18,940 - $26,990	-1,000 Closed	0 $0
Q4 2020 Jan 27, 2021	SELL	$13.8 - $27.62 $55,200 - $110,480	-4,000 Reduced 80.0%	1,000 $28,000
Q3 2020 Nov 03, 2020	BUY	$14.05 - $22.6 $63,225 - $101,700	4,500 Added 900.0%	5,000 $70,000
Q2 2020 Jul 27, 2020	BUY	$7.34 - $20.84 $3,670 - $10,420	500 New	500 $10,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.